AIM IMMUNOTECH INC. Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss
AIM IMMUNOTECH INC. (AIM) reported Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss of $17.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments · last filed 2026-03-27
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-12-31 was $0.00.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2025-09-30 was -$1.00K, a 100.37% decline year-over-year.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-12-31 was -$188.00K, a 146.88% decline year-over-year.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2024-09-30 was $273.00K.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2025 was $17.00K.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was -$93.00K, a 146.50% decline from fiscal 2023.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $200.00K.
- AIM IMMUNOTECH INC. marketable securities, gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was -$1.68M.
| Period end | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$1.00K derived: sum of 2 quarters · filed 2026-03-27 | $17.00K 10-K · filed 2026-03-27 | |
| 2025-09-30 | -$1.00K 10-Q · filed 2025-11-17 | $17.00K 10-Q · filed 2025-11-17 | ||
| 2025-06-30 | $17.00K 10-Q · filed 2025-08-14 | |||
| 2024-12-31 | -$188.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $85.00K derived: sum of 2 quarters · filed 2026-03-27 | $0.00 derived: sum of 3 quarters · filed 2026-03-27 | -$93.00K 10-K · filed 2026-03-27 |
| 2024-09-30 | $273.00K 10-Q · filed 2025-11-17 | $188.00K derived: sum of 2 quarters · filed 2025-11-17 | $95.00K 10-Q · filed 2025-11-17 | $497.00K derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | -$85.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$177.00K 10-Q · filed 2025-08-14 | $224.00K derived: sum of 3 quarters · filed 2025-08-14 | -$86.00K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$92.00K 10-Q · filed 2024-05-15 | $309.00K derived: sum of 2 quarters · filed 2025-03-27 | -$1.00K derived: sum of 3 quarters · filed 2025-03-27 | -$95.00K derived: sum of 4 quarters · filed 2025-03-27 |
| 2023-12-31 | $401.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $91.00K derived: sum of 2 quarters · filed 2025-03-27 | -$3.00K derived: sum of 3 quarters · filed 2025-03-27 | $200.00K 10-K · filed 2025-03-27 |
| 2023-09-30 | -$310.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$404.00K derived: sum of 2 quarters · filed 2024-11-14 | -$201.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $109.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $203.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$1.68M 10-K · filed 2024-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Silexion Therapeutics Corp (SLXN) | $0.001B |